Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Richardet, Katriina Peltola, Ajjai S. Alva, Michael Carducci, John WagstaffChristine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas C. Gauler, Christian K. Kollmannsberger, Fabio A. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir

IM-Hem Onc Kidney
Internal Medicine

Research output: Contribution to journal › Article › peer-review

201 Scopus citations

Sort by
Weight
Alphabetically

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

Fingerprint

Medicine & Life Sciences